Lexicon Genetics Incorporated (Nasdaq: LEXG) recently announced its commencement of formal preclinical development for LX2931 in preparation for an Investigational New Drug (IND) application.
LX2931 is the company's novel, orally-available small molecule compound with potential application in the treatment of autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
According to Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer:
"LX2931 represents a potential new mechanism for the treatment of immune system disorders characterized by inappropriate lymphocyte activation. LX2931 is the third internal Lexicon drug discovery program to enter formal preclinical development.
We expect additional programs within our pipeline, such as LG267, to reach this milestone within the next few months. We continue to anticipate that we will file an IND for LX1031 for irritable bowel syndrome later this year."
LX2931, in preclinical models, demonstrated inhibition of the in vivo activity of an enzyme that is associated with immune response and lymphocyte migration.
Find more details from the press release.
Comment Preview